# A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor

> **NCT03219554** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 33 (estimated)

## Conditions studied

- Thymic Cancer

## Interventions

- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03219554
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08
- **Primary completion:** 2019-12
- **Final completion:** 2020-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219554, "A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03219554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*